Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2017

View Archived Issues

Promius Pharma's phase II study of intranasal sumatriptan meets primary endpoint

Biomarkers predict success of Tessa Therapeutics CTL immunotherapy in nasopharyngeal cancer

Subcutaneous Orencia available for patients 2 years of age and older

Genentech returning rights to GDC-0919 to NewLink Genetics

Cascadian Therapeutics' tucatinib receives FDA orphan drug designation

FDA grants fast track status to Aeolus Pharmaceuticals' AEOL-10150

Meiji Seika Pharma's TS-3112 shows promise against antibiotic-resistant bacteria

Valeant enters agreement to sell iNova Pharmaceuticals

2X Oncology obtains IND application for 2X-111 from 2-BBB Medicines

Upadacitinib meets all primary and secondary endpoints in phase III SELECT-NEXT study

TSRI and ShangPharma Innovation enter translational research collaboration

Chitinase inhibitor OAT-889 effective in models of airway inflammation

FDA grants orphan drug status to tavokinogene telsaplasmid in unresectable metastatic melanoma

FDA requests removal of Opana ER from the market

Inovio Pharmaceuticals initiates REVEAL phase III program for VGX-3100

Iproteos discovers novel matrix metalloproteinase-2/9 inhibitors

Merck & Co. describes new oxysterols receptor LXR-beta agonists

Sensorion announces positive phase I results for SENS-401

Vitros NephroCheck test becomes available in Europe

Lilly and KeyBioscience enter strategic collaboration

Wakunaga Pharmaceutical's WFQ-228 and WFQ-253 show promise for hospital-acquired pneumonia

Burtomab granted breakthrough therapy designation for advanced form of pediatric neuroblastoma

Kissei gains exclusive rights to develop and commercialize avacopan in Japan

Eureka Therapeutics and City of Hope enter agreement for phase I clinical testing of ET1402L1 CAR-T

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...